Bapineuzumab, an experimental drug developed for treating Alzheimer's disease, has become a cause of huge disappointment for the manufacturing companies Pfizer and Johnson & Johnson, a recent report says. Since, the same has failed in its late-stage trial, however was being hoped to prove a highly effective medication over a previous one.
Irish business Elan along with its American cohorts has thus decided to cancel its testing in a further trial. Also, the two industrialized groups have declared the halt of any more trial as the failure has already brought their shares down. They are dispirited high because an earlier study had also shown collapse of a drug to slow down dementia's growth.
As per the findings, the drug was given to some patients with cognitive problems, while some others were given a placebo to fight the same. And no more than a slight difference was seen in the effects of the two medications.
Now, abandonment of the IV version is to be followed by a new drug undergoing a trial with results almost by the end of this year. The jab named solanezumab is being developed by Eli Lilly, and for the success of the same, all have crossed their fingers, the report concludes.
Good News USA
- Vodafone NZ’s new ‘Red Home’ packages will offer UFB and 150 TV channels
- Vodafone NZ’s full-year profit plunged by more than two-thirds to $56 million
- Vodafone adding 34 European countries to ‘AU$5 per day’ international roaming option
- Telstra launches its new ‘Every Day Connect Data Share Packages’
- Voyager signs “multimillion-dollar deal” with submarine cable group Hawaiki